Mystic Pharmaceuticals Receives U.S. Patent for Innovative Unit Dose Packaging and Delivery Technology for Drugs and Biologics 

AUSTIN, TX – November 9, 2011 (Business Wire) -- Mystic Pharmaceuticals, Inc. announces today that it has been granted U.S. Patent No. 8,047,204, “Combination Unit Dose Dispensing Containers I” for a novel unit dose blister packaging technology. This packaging technology is a key element of the company’s VersiDoserTM and VRx2TM drug and biologic delivery systems. Mystic’s delivery platforms provide preservative free unit dose packaging and devices for precision delivery of drugs and biologics.

President and CEO of Mystic, Timothy Sullivan states that, “We continue to expand the breadth and depth of our delivery platform technologies with this latest advance. Our novel unit dose blister packaging combined with patient friendly delivery systems enable manufacturers to extend product life for branded products beyond patent expiry and retain market exclusivity. With Mystic’s VersiDoserTM and VRx2TM delivery systems patients can precisely and consistently self-administer medications to the eye, nose, mouth, ear or topically to the skin. Drug delivery enhanced pharmaceuticals offer the patient a superior experience in terms of ease of use, convenience and therapeutic results.”

Drug delivery enhanced products that provide improved benefits to the consumer and extend or establish market exclusivity has emerged as a compelling strategy for big pharma, specialty pharma and biotech manufacturers for product line extension and competitive differentiation. Mystic delivery systems are designed to meet the diverse demands of manufacturers and consumers at a cost competitive price point.

About Mystic Pharmaceuticals, Inc.